Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03567135 : Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma
Phase
AgesMin: 18 Years Max: 70 Years
Eligibility
Search Criteria:

1. Subjects received anti-angiogenesis drugs simultaneous accompanied with radio-and
chemotherapy in Fuzhou Zongyuan since October, 2017;

2. Age: 18-70 years;

3. The first surgical pathology was diagnosed as glioblastoma, WHO grade IV;

4. Patients who have previously received no more than one surgical treatment;

5. ECOG performance status: 0-2;

6. Survival expectation=3 months.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03567135      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740